Twist Bioscience Corp.
- TWST ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- South San Francisco, CA
- 979 employees
- CIK 0001581280
Updated from SEC filings through
Top things to know
Executives
-
Emily M. Leproust Chief Executive Officer 4, 2026-09-25 -
Adam Laponis Chief Financial Officer 4, 2026-08-25 - Robert F. Werner Chief Accounting Officer 4, 2026-09-10
- Patrick John Finn President and COO 4, 2026-08-25
- Paula Green SVP of Human Resources 4, 2026-09-23
-
Dennis Cho Chief Legal Officer and Corporate Secretary DEF 14A, 2026-01-06
Twist Bioscience Corp is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in South San Francisco, CA. It trades as TWST on Nasdaq. Revenue was $377M in the fiscal year ending September 30, 2025, +20.3% from the year before. It reported about 979 employees. Emily M. Leproust is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $377M 10-K, 2025-11-17 | $313M 10-K, 2025-11-17 | $245M 10-K, 2025-11-17 | $204M 10-K, 2024-11-18 | $132M 10-K, 2023-11-21 |
| Operating income | -$136M 10-K, 2025-11-17 | -$221M 10-K, 2025-11-17 | -$217M 10-K, 2025-11-17 | -$235M 10-K, 2024-11-18 | -$153M 10-K, 2023-11-21 |
| SG&A | $247M 10-K, 2025-11-17 | $218M 10-K, 2025-11-17 | $190M 10-K, 2025-11-17 | $213M 10-K, 2024-11-18 | $136M 10-K, 2023-11-21 |
| Net income | -$77.7M 10-K, 2025-11-17 | -$209M 10-K, 2025-11-17 | -$205M 10-K, 2025-11-17 | -$218M 10-K, 2024-11-18 | -$152M 10-K, 2023-11-21 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Emily M. Leproust CEO & Founder of Twist Bioscience | At the Helm of the Biology Revolution where Customization meets Scale | Chief Executive Officer | 4, 2026-09-25 |
| Robert Ragusa | Board member (per proxy) bio: Chief Executive Officer | DEF 14A, 2026-01-06 |
| Adam Laponis Chief Financial Officer | Chief Financial Officer | 4, 2026-08-25 |
| Robert F. Werner Chief Accounting Officer at Twist | Chief Accounting Officer | 4, 2026-09-10 |
| Patrick John Finn | President and COO | 4, 2026-08-25 |
| Dennis Cho | Named in proxy bio: Chief Legal Officer and Corporate Secretary | DEF 14A, 2026-01-06 |
| Robert Werner | Named in proxy bio: Vice President, Chief Accounting Officer | DEF 14A, 2026-01-06 |
| Paula Green Senior Vice President Human Resources at Twist Bioscience | SVP of Human Resources | 4, 2026-09-23 |
| Jan Johannessen | Board member (per proxy) bio: Director | DEF 14A, 2026-01-06 |
What Twist Bioscience Corp does
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.
Item 1. Business, 10-K for the year ending September 30, 2025
Shares and governance
| Shares outstanding | 62.7 million (as of July 29, 2026) | 10-Q, August 3, 2026 |
|---|---|---|
| Public float | $2.3B (as of March 31, 2025) | 10-K, November 17, 2025 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 3, 2026 |
| Latest proxy statement | Meeting February 5, 2026 (filed January 6, 2026) | DEF 14A, January 6, 2026 |
| Auditor | Ernst & Young LLP (San Mateo, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 3, 2026 | Dennis Cho See Remarks | Sale | 949 | $128K | Form 4, November 5, 2026 |
| November 3, 2026 | Patrick John Finn President and COO | Sale | 2,565 | $347K | Form 4, November 5, 2026 |
| November 3, 2026 | Paula Green SVP of Human Resources | Sale | 1,007 | $136K | Form 4, November 5, 2026 |
| November 3, 2026 | Emily M. Leproust Chief Executive Officer | Sale | 4,573 | $619K | Form 4, November 5, 2026 |
| November 3, 2026 | Robert F. Werner Chief Accounting Officer | Sale | 148 | $20K | Form 4, November 5, 2026 |
| October 23, 2026 | Patrick John Finn President and COO | Sale | 2,245 | $302K | Form 4, October 27, 2026 |
| October 9, 2026 | Adam Laponis Chief Financial Officer | Sale | 2,462 | $385K | Form 4, October 13, 2026 |
| October 5, 2026 | Emily M. Leproust Chief Executive Officer | Sale | 4,548 | $919K | Form 4, October 7, 2026 |
Recent 8-K events
- 8-K filed 2026-08-19
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-19
- Item 8.01 Other events
- 8-K filed 2026-08-05
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-17
- Item 3.02 Unregistered sales of equity securities
- Item 8.01 Other events
- 8-K filed 2026-02-06
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-02-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-14
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Twist Bioscience Corp
- What does Twist Bioscience Corp do?
- In its own words, from Item 1 of its 10-K: "At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us."
- What is Twist Bioscience Corp's revenue?
- $377M for the fiscal year ending September 30, 2025, from its 10-K filed November 17, 2025.
- Is Twist Bioscience Corp profitable?
- Twist Bioscience Corp reported net income of -$77.7M for the fiscal year ending September 30, 2025.
- How many employees does Twist Bioscience Corp have?
- About 979 as of September 30, 2025, as stated in its annual report.
- Who is the CEO of Twist Bioscience Corp?
- Emily M. Leproust, Chief Executive Officer, as named in a 4 filed September 25, 2026.
- Who is the CFO of Twist Bioscience Corp?
- Adam Laponis, Chief Financial Officer, as named in a 4 filed August 25, 2026.
- Where is Twist Bioscience Corp headquartered?
- South San Francisco, CA.
- What is Twist Bioscience Corp's stock ticker?
- TWST on Nasdaq.
- What industry is Twist Bioscience Corp in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Twist Bioscience Corp's website?
- twistbioscience.com.
- When does Twist Bioscience Corp report earnings next?
- November 12, 2026 at 08:30. Source: pg_future_events.
- Is Twist Bioscience Corp a public company?
- Yes. Twist Bioscience Corp files with the SEC under CIK 0001581280 and trades as TWST.
- Who audits Twist Bioscience Corp?
- Ernst & Young LLP, San Mateo, California, as named in its latest annual report (10-K).
- How many shares of Twist Bioscience Corp are outstanding?
- 62.7 million shares as of July 29, 2026, from its 10-Q filed August 3, 2026.
- What is Twist Bioscience Corp's public float?
- $2.3B as of March 31, 2025, as reported on the cover of its 10-K filed November 17, 2025.
- How many business segments does Twist Bioscience Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 3, 2026.
- When is Twist Bioscience Corp's annual shareholder meeting?
- February 5, 2026, per its proxy statement (DEF 14A) filed January 6, 2026.
- Have Twist Bioscience Corp insiders traded stock recently?
- Since May 28, 2026, officers and directors reported 57 open-market sales worth about $130M and 0 purchases on Forms 4 and 5. The most recent: Dennis Cho (See Remarks) sold 949 shares on November 3, 2026.